World

Gold rises on worse than expected economic data

Aug 30, 2023

Washington [US], August 30: Gold futures on the COMEX division of the New York Mercantile Exchange rose on Tuesday as U.S. economic data came in worse than expected.
The most active gold contract for December delivery rose 18.30 U.S. dollars, or 0.94 percent, to close at 1,965.10 dollars per ounce.
The Conference Board, a business research group, reported Tuesday that its consumer confidence index tumbled to 106.1 in August from a revised 114 in July. Analysts were expecting a reading of 116.
The U.S. Labor Department reported that U.S. job openings dropped to 8.8 million in July, the fewest since March 2021 and down from 9.2 million in June.
The U.S. dollar index and Treasury yields dropped following weaker than expected economic data.
Investors are also waiting for the gross domestic product report due out Wednesday, July personal consumption expenditure index on Thursday and August U.S. employment report on Friday.
Silver for September delivery rose 53.60 cents, or 2.21 percent, to close at 24.788 dollars per ounce. Platinum for October delivery rose 13.90 dollars, or 1.43 percent, to close at 986.10 dollars per ounce
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025